Lanreotide [Neurosurgery Wiki]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
====== Lanreotide ======

see [[Lanreotide for Acromegaly]]



Lanreotide (as lanreotide acetate) is manufactured by Ipsen, and marketed under the trade name Somatuline. It is available in several countries, including the United Kingdom, Australia and Canada, and was approved for sale in the United States by the Food and Drug Administration (FDA) on August 30, 2007.
----
Zhang et al., described a patient with a [[vasopressin]]-secreting atypical [[neurocytoma]] of the [[sella]]r and [[cavernous sinus]] region. Following [[subtotal resection]] via endoscopic [[transsphenoidal]] surgery, the [[residual]] tumor showed increased [[FDG]] uptake and high [[somatostatin receptor]] expression on a [[68Ga]]-DOTA-TATE PET/CT scan. [[Somatostatin receptor ligand]] (SRL) therapy with [[lanreotide]] (120 mg Q28d) was initiated, and 4 years later the residual tumor remains stable with decreased FDG tumor uptake. Immunocytochemical [[somatostatin receptor]] 2 (SSTR2) and SSTR5 expression was further confirmed in > 80% in a series of neurocytoma tissues.

They described the first use of SRL therapy in atypical NC and the results support consideration of adjuvant SRL therapy in NC refractory to surgical removal. The findings further raise the possibility of SSTR-directed [[peptide]] receptor [[radionuclide]] therapy (PRRT) as NC therapy
((Zhang D, Kim SSR, Kelly DF, Asa SL, Movassaghi M, Mareninov S, Yong WH,
Cloughesy TF, Rodriguez FJ, McKeever P, Qian J, Li JY, Mao Q, Newell KL, Green
RM, Welsh CT, Xiong Z, Heaney AP. Somatostatin Receptor Ligand Therapy-A Novel
Therapy for Neurocytoma. J Clin Endocrinol Metab. 2019 Feb 5. doi:
10.1210/jc.2018-02419. [Epub ahead of print] PubMed PMID: 30722009.
)).
----


The current long-acting [[somatostatin analog]]s SAs, lanreotide and [[octreotide]], show equivalence in their control of symptoms and no significant difference in their ability to normalize serum [[growth hormone]] GH and [[insulin like growth factor]] IGF-1
((Melmed S, Colao A, Barkan A, et al. Acromegaly Consensus Group Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94(5):1509–1517.)).

Although a number of studies concerning presurgical treatment with lanreotide or octreotide exist, there are few prospective large-scale randomized trials comparing the effects of lanreotide and octreotide, and thus no definite conclusion has yet been achieved.


Lanreotide ATG and octreotide LAR may therefore have similar effects in clinic according to the current data
((Wang JW, Li Y, Mao ZG, Hu B, Jiang XB, Song BB, Wang X, Zhu YH, Wang HJ.
Clinical applications of somatostatin analogs for growth hormone-secreting
pituitary neuroendocrine tumors. Patient Prefer Adherence. 2014 Jan 6;8:43-51. eCollection
2014. Review. PubMed PMID: 24421637; PubMed Central PMCID: PMC3888346.)).

===== References =====